Skip to main content
. 2016 Sep 18;2016(9):CD006992. doi: 10.1002/14651858.CD006992.pub2

McGill 2015.

Methods Data for participants in two phase 3 trials with linagliptin who were receiving insulin were analysed separately (n = 811)
Participants Type 2 diabetes mellitus participants with chronic kidney disease
Interventions Linagliptin + insulin vs placebo + insulin
Outcomes HbA1c, (severe) hypoglycaemia
Notes Inadequate control needs to be checked